endTB-Q

Submitted by zaidtanvir on

This is a Phase III, randomized, controlled, open-label, multi-country trial evaluating the efficacy of new combination regimens for treatment of fluoroquinolone-resistant MDR-TB.

WHO Updates Treatment Guidance to Shorter, Novel Regimens for Drug-Resistant Tuberculosis

Earlier this week, the World Health Organization (WHO) released a rapid communication which detailed the upcoming changes to the treatment guidance for drug-resistant tuberculosis (DR-TB). These guidelines are used to inform national TB programmes globally on how to treat patients with these difficult-to-treat forms of TB.

Online Consultation on Global Plan to End TB 2023-2030

On April 01, 2022, the Stop TB Partnership launched the second online consultation for the new Global Plan to End TB 2023-2030. Over the years, the Global Plans have been important tools for advocacy and resource mobilization, and served as a reference document for donors and stakeholders. In May 2021, the Stop TB Partnership held its first online consultation to gather ideas from diverse stakeholders that would guide the direction of the Global Plan 2023 to 2030.

ERA4TB (European Regimen Accelerator for Tuberculosis)

Submitted by barbara on

January 29, 2020. Press Release. ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative devoted to accelerate the development of new treatment regimens for tuberculosis.  With a team of more than thirty organizations and a budget of over 200 million euros,
ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new

TBI-223 Phase 1 MAD

Submitted by barbara on

This is a partially-blinded, placebo-controlled, randomized multiple ascending dose (MAD) study toinclude a single dose food-effect study to evaluate the safety, tolerability, and the PK profile of TBI-223. Thirty-six (36) subjects will be enrolled in 3 cohorts with 12 subjects per cohort. Within each cohort, 9 subjects will be assigned to receive active treatment and 3 subjects will receive placebo.  Drug: 1800 mg TBI-223, 2400mg TBI-223, 3000mg TBI-223 vs Placebo.

Phase 2. Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis

Submitted by barbara on

Arm  Intervention/treatment 
Experimental: TBA-7371 100 mg QD Drug: TBA-7371

Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
Experimental: TBA-7371 100 mg BID Drug: TBA-7371

Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.

Pages

Subscribe to Working Group for New TB Drugs RSS